H19 and microRNA-675 as Potential Biomarkers for Prostate Cancer

Prostate cancer (PCa) is considered the most common malignancy in men globally. Although prostate specific antigen (PSA) is still the only universally utilized biomarker related to prostate cancer, however PSA is not an ideal biomarker and its level can be altered by many factors. The aim of this study is to study serum H19 and miR-675 expression in prostate cancer patients and their potential diagnostic & prognostic significance targeting to find a noninvasive biomarker. This study comprised 25 PCa patients and 25 healthy controls. The expression of serum H19 and miR-675 was detected by real-time polymerase chain reaction while N-Cadherin as an adhesion marker was measured by ELISA (enzyme-linked immunosorbent assay). The expression levels of serum H19 and miR-675 were increased in prostate cancer patients compared with controls. Also serum level of N-cadherin was higher in prostate cancer patients. Upregulation of H19 and miR-675 correlated with PCa metastasis and higher Gleason score. By using the ROC curve, the sensitivity of H19 and miR-675 was higher than PSA for the diagnosis of PCa. The results suggest that H19 and miR-675 expression could be considered potential noninvasive diagnostic and prognostic biomarkers for PCa.